Articles & Issues
- Language
- English
- Conflict of Interest
- In relation to this article, we declare that there is no conflict of interest.
- Publication history
-
Received October 5, 2010
Accepted December 4, 2010
-
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/bync/3.0) which permits
unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright © KIChE. All rights reserved.
All issues
Therapeutic effect of chitosan modification on salmon-calcitonin-loaded PLGA nanoparticles
1Department of Smart Foods and Drugs, Inje University, Gimhae, Gyeongnam 621-749, Korea 2Department of Pharmaceutical Engineering, Inje University, Gimhae, Gyeongnam 621-749, Korea
pegchoi@inje.ac.kr
Korean Journal of Chemical Engineering, June 2011, 28(6), 1406-1411(6), 10.1007/s11814-010-0508-9
Download PDF
Abstract
Although salmon-calcitonin (sCT) has been known as a potent drug for the treatment of osteoporosis, its oral dosage form products have not been commercially available primarily due to a poor oral bioavailability. Chitosan has been extensively examined as a potential oral absorption enhancer, whereas encapsulation with PLGA has been widely studied to address the delivery problems of typical peptide drug molecules. We investigated the mechanism and therapeutic effect of chitosan modification on the sCT-loaded PLGA nanoparticles. Chitosan was added onto these particles in two ways: by incorporation during W/O/W emulsification and by solid dipping. Particles were characterized by particle size analyzer, Zeta potential analyzer, scanning electron microscopy, and so forth. Nano-sized particles of 430-590 nm in fairly spherical shape with a narrow size distribution were produced. The PLGA encapsulation efficiency greater than 50% of added sCT was achieved regardless of chitosan modification. It turned out that sCT-loaded PLGA particles with chitosan modified during W/O/W emulsification (referred to as sCT-PLGA-CHT1) showed better therapeutic behavior in terms of sustained release effects as well as short-period hypocalcemic effects than the others. It was concluded that the beneficial effect was greatly associated with the formation of embedded structure of chitosan molecules when particles were modified with chitosan.
References
Hejazi R, Amiji M, J. Control. Release., 89, 151 (2003)
Issa MM, Koping-Hoggard M, Artursson P, Drug Discovery Today: Technol., 2, 1 (2005)
Sinswat P, Tengamnuay P, Int. J. Pharmaceutics., 257, 15 (2003)
Sui W, Huang L, Wang J, Bo Q, Colloid. Surf. B: Biointerf., 65, 69 (2008)
Yu CY, Yin BC, Zhang W, Cheng SX, Zhang XZ, Zhuo RX, Colloid. Surf. B: Biointerf., 68, 245 (2009)
Yamamoto H, Kuno Y, Sugimoto S, Takeuchi H, Kawashima Y, J. Control. Release., 102, 373 (2005)
Nafee N, Taetz S, Schneider M, Schaefer UF, Lehr CM, Nanomedicine., 3, 173 (2007)
Tahara K, Sakai T, Yamamoto H, Takeuchi H, Kawashima Y, Int. J. Pharmaceutics., 354, 210 (2008)
Yang R, Yang SG, Shim WS, Cui F, Cheng G, Kim IW, Kim DD, Chung SJ, Shim CK, J. Pharm. Sci., 98, 970 (2009)
Yang R, Shim WS, Cui FD, Cheng G, Han X, Jin QR, Kim DD, Chung SJ, Shim CK, Int. J. Pharmaceutics., 371, 142 (2009)
Manca ML, Mourtas S, Dracopoulos V, Fadda AM, Antimisiaris SG, Colloid. Surf. B: Biointerf., 62, 220 (2008)
Manca ML, Loy G, Zaru M, Fadda AM, Antimisiaris SG, Colloid. Surf. B: Biointerf., 67, 166 (2008)
Zaru M, Manca ML, Fadda AM, Antimisiaris SG, Colloid. Surf. B: Biointerf., 71, 88 (2009)
Garcia-Fuentes M, Prego C, Torres D, Alonso MJ, Euro. J. Pharm. Sci., 25, 133 (2005)
Lee JS, Kim JS, Lee HG, Colloid. Surf. B: Biointerf., 70, 213 (2009)
Coppi G, Iannuccelli V, Int. J. Pharmaceutics., 367, 127 (2009)
Jang JY, Kwon BS, Lee HE, Kim DH, Kang HK, Kang JS, Lee S, Choi GJ, J. Ind. Eng. Chem., 13(6), 1043 (2007)
Jung TS, Kwon BS, Lee HE, Kim AY, Lee MJ, Park CR, Kang HK, Kim YD, Lee SK, Kang JS, Choi GJ, Korean J. Chem. Eng., 26(1), 131 (2009)
Smith PK, Anal. Biochem., 159, 76 (1985)
Kaplan LA, Pesce AJ, Kaczmierczak SC, Clinical Chemistry : Theory, Analysis, Correlation. 4th Ed., Mosby Inc., St. Louis (2003)
Prego C, Garcia M, Torres D, Alonso MJ, J. Control. Release., 101, 151 (2005)
Issa MM, Koping-Hoggard M, Artursson P, Drug Discovery Today: Technol., 2, 1 (2005)
Sinswat P, Tengamnuay P, Int. J. Pharmaceutics., 257, 15 (2003)
Sui W, Huang L, Wang J, Bo Q, Colloid. Surf. B: Biointerf., 65, 69 (2008)
Yu CY, Yin BC, Zhang W, Cheng SX, Zhang XZ, Zhuo RX, Colloid. Surf. B: Biointerf., 68, 245 (2009)
Yamamoto H, Kuno Y, Sugimoto S, Takeuchi H, Kawashima Y, J. Control. Release., 102, 373 (2005)
Nafee N, Taetz S, Schneider M, Schaefer UF, Lehr CM, Nanomedicine., 3, 173 (2007)
Tahara K, Sakai T, Yamamoto H, Takeuchi H, Kawashima Y, Int. J. Pharmaceutics., 354, 210 (2008)
Yang R, Yang SG, Shim WS, Cui F, Cheng G, Kim IW, Kim DD, Chung SJ, Shim CK, J. Pharm. Sci., 98, 970 (2009)
Yang R, Shim WS, Cui FD, Cheng G, Han X, Jin QR, Kim DD, Chung SJ, Shim CK, Int. J. Pharmaceutics., 371, 142 (2009)
Manca ML, Mourtas S, Dracopoulos V, Fadda AM, Antimisiaris SG, Colloid. Surf. B: Biointerf., 62, 220 (2008)
Manca ML, Loy G, Zaru M, Fadda AM, Antimisiaris SG, Colloid. Surf. B: Biointerf., 67, 166 (2008)
Zaru M, Manca ML, Fadda AM, Antimisiaris SG, Colloid. Surf. B: Biointerf., 71, 88 (2009)
Garcia-Fuentes M, Prego C, Torres D, Alonso MJ, Euro. J. Pharm. Sci., 25, 133 (2005)
Lee JS, Kim JS, Lee HG, Colloid. Surf. B: Biointerf., 70, 213 (2009)
Coppi G, Iannuccelli V, Int. J. Pharmaceutics., 367, 127 (2009)
Jang JY, Kwon BS, Lee HE, Kim DH, Kang HK, Kang JS, Lee S, Choi GJ, J. Ind. Eng. Chem., 13(6), 1043 (2007)
Jung TS, Kwon BS, Lee HE, Kim AY, Lee MJ, Park CR, Kang HK, Kim YD, Lee SK, Kang JS, Choi GJ, Korean J. Chem. Eng., 26(1), 131 (2009)
Smith PK, Anal. Biochem., 159, 76 (1985)
Kaplan LA, Pesce AJ, Kaczmierczak SC, Clinical Chemistry : Theory, Analysis, Correlation. 4th Ed., Mosby Inc., St. Louis (2003)
Prego C, Garcia M, Torres D, Alonso MJ, J. Control. Release., 101, 151 (2005)
